CN116390725A - 用于治疗肺部炎症和间质性肺病的羟基吡格列酮 - Google Patents

用于治疗肺部炎症和间质性肺病的羟基吡格列酮 Download PDF

Info

Publication number
CN116390725A
CN116390725A CN202180043546.3A CN202180043546A CN116390725A CN 116390725 A CN116390725 A CN 116390725A CN 202180043546 A CN202180043546 A CN 202180043546A CN 116390725 A CN116390725 A CN 116390725A
Authority
CN
China
Prior art keywords
thiazolidine
dione
ethoxy
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043546.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·马蒂内尔皮德蒙特
M·P·皮兹库塔拉朗扎
A·维拉塔萨乌拉
E·特拉维洛佩茨
S·玛丽亚波立
N·伊斯盖尔多尤赛罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of CN116390725A publication Critical patent/CN116390725A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180043546.3A 2020-04-30 2021-04-30 用于治疗肺部炎症和间质性肺病的羟基吡格列酮 Pending CN116390725A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
EP20382356.2 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (1)

Publication Number Publication Date
CN116390725A true CN116390725A (zh) 2023-07-04

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043546.3A Pending CN116390725A (zh) 2020-04-30 2021-04-30 用于治疗肺部炎症和间质性肺病的羟基吡格列酮

Country Status (11)

Country Link
US (1) US20230172921A1 (https=)
EP (1) EP4142720A1 (https=)
JP (1) JP2023525981A (https=)
KR (1) KR20230035522A (https=)
CN (1) CN116390725A (https=)
AU (1) AU2021265345A1 (https=)
BR (1) BR112022021951A2 (https=)
CA (1) CA3180351A1 (https=)
IL (1) IL297771A (https=)
MX (1) MX2022013021A (https=)
WO (1) WO2021220250A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4642456A1 (en) * 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
US20200093812A1 (en) * 2016-12-01 2020-03-26 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-Hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for Treating Nonalcoholic Fatty Liver Disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590774A (en) * 2008-08-07 2012-09-28 Pulmagen Therapeutics Inflammation Ltd Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases
WO2011047048A1 (en) * 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
EA202091120A3 (ru) 2014-04-02 2020-12-30 Минорикс Терапьютикс С.Л. Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
CN112823004A (zh) * 2018-06-06 2021-05-18 米尼奥尔克斯治疗有限公司 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
US20200093812A1 (en) * 2016-12-01 2020-03-26 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-Hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for Treating Nonalcoholic Fatty Liver Disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELENA CARBONI ET AL: "Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?", MEDICAL HYPOTHESES, no. 140, 22 April 2020 (2020-04-22), pages 2 *
UWE MEYA ET AL: "A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Biomarkers of MIN-102 (Leriglitazone) (4149)", NEUROLOGY, no. 94, 14 April 2020 (2020-04-14) *
吴荣;孙宇楠;张振勇;曾越灿;曹硕;: "吡格列酮在大鼠放射性肺纤维化中保护作用的研究", 实用药物与临床, no. 01, 15 January 2015 (2015-01-15) *

Also Published As

Publication number Publication date
CA3180351A1 (en) 2021-11-04
WO2021220250A1 (en) 2021-11-04
MX2022013021A (es) 2023-01-16
IL297771A (en) 2022-12-01
JP2023525981A (ja) 2023-06-20
AU2021265345A1 (en) 2022-12-08
KR20230035522A (ko) 2023-03-14
EP4142720A1 (en) 2023-03-08
US20230172921A1 (en) 2023-06-08
BR112022021951A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
US20230241014A1 (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20110295365A1 (en) Anti-viral compositions and methods for administration
US20260041660A1 (en) Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
KR20240073720A (ko) Covid-19 질환을 치료하는 신규 조성물 및 방법
Kumar et al. The chronicle of COVID-19 and possible strategies to curb the pandemic
CN116390725A (zh) 用于治疗肺部炎症和间质性肺病的羟基吡格列酮
Pickering et al. Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages
HK40096631A (zh) 用於治疗肺部炎症和间质性肺病的羟基吡格列酮
JP2023536591A (ja) リラグルチドおよびゲフィチニブの抗ウイルスとしての使用
US20150165009A1 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto
KR20230021009A (ko) 항바이러스 치료로서의 아젤라스틴
EP4183396A1 (en) Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia
WO2016149045A1 (en) Reversal of latency of retroviruses with a galectin protein
EP3720440A1 (en) Treatment of rsv with combination product
WO2023280828A1 (en) A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
RU2837859C1 (ru) Лечение коронавирусной инфекции
Pérez et al. Evaluation of immune response, comorbidities and immunomodulation in SARS-CoV2 pandemic
Mateen et al. IMMUNOPATHOGENESIS AND POSSIBLE THERAPEUTIC INTERVENTIONS FOR COVID-19: AN UPDATE
WO2025235945A1 (en) Methods of treating viral infections using a fusion inhibitor
US20230181598A1 (en) FORMULATIONS AND METHODS OF TREATING COVID-19 AND PREVENTING INFECTION WITH SARS-CoV-2
EA051538B1 (ru) Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19
Filon Antiviral Therapy for Progressive Multifocal Leukoencephalopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096631

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230704